Tango Therapeutics, Inc. filings document a clinical-stage precision oncology business and its Nasdaq-listed common stock. Current reports disclose operating and financial results, business highlights for vopimetostat and related development programs, material agreements, capital-raising arrangements such as at-the-market common stock sales, and updates to governance and executive leadership.
Proxy and compensation disclosures cover board matters, executive pay, pay-versus-performance data, equity awards, and shareholder voting matters. The company’s filings also address officer appointments and departures, separation and employment agreements, compensatory arrangements, capital structure, risk factors, and other material events affecting its biotechnology operations.
Third Rock Ventures IV, L.P. reported a sale of 500,000 shares of Tango Therapeutics, Inc. (TNGX) executed on 09/25/2025 at a weighted-average price of $8.017 per share. After the sale, the reporting person holds 13,863,975 shares, which are directly held by Third Rock Ventures IV, L.P. The filing identifies Third Rock Ventures GP IV, L.P. and TRV GP IV, LLC as related entities that disclaim beneficial ownership except to the extent of any pecuniary interest. The form was signed by Kevin Gillis on 09/29/2025.
Tango Therapeutics, Inc. (TNGX) Form 144 reports a proposed sale of 500,000 shares of common stock through BTIG, LLC on 09/25/2025 with an aggregate market value of $3,900,000.00. The shares were originally acquired on 07/24/2017 as a pre-IPO investment from Tango Therapeutics, Inc., and payment was by wire. The filing also discloses multiple recent sales by Third Rock Ventures IV, L.P. during Aug–Sep 2025 totaling several transactions of common stock with gross proceeds reported for each sale.
Tango Therapeutics Schedule 13G disclosure: Multiple related entities controlled by Raymond Debbane report beneficial ownership of common stock. Invus Public Equities directly holds 5,082,716 shares (4.6%) and Avicenna Life Sci Master Fund LP directly holds 800,472 shares (0.7%), for a combined position reported by the related reporting persons. Mr. Raymond Debbane is identified as controlling the chain of entities and is reported as beneficial owner of 5,883,188 shares (5.3%) based on 111,260,247 shares outstanding. The filing certifies the holdings were not acquired to change or influence control of the issuer.
Third Rock Ventures entities reported an insider sale of Tango Therapeutics (TNGX) common stock. On 09/16/2025 the reporting persons sold 363,541 shares at a weighted-average price of $7.04 per share (sales ranged $7.00–$7.19). After the sale, Third Rock Ventures IV, L.P. directly held 14,363,975 shares. The filing identifies the reporting parties as a director and a greater-than-10% owner and includes standard GP disclaimers that the GP entities disclaim beneficial ownership except to the extent of pecuniary interest. The Form 4 was signed by Kevin Gillis on 09/17/2025.
Tango Therapeutics, Inc. (TNGX) Form 144 notifies a proposed sale of 363,541 common shares through BTIG, LLC with an aggregate market value of $2,672,026.35, against 111,260,247 shares outstanding. The approximate sale date is 09/16/2025. The filing shows the shares to be sold were acquired in two pre-IPO wire transactions on 03/23/2017 (23,067 shares) and 07/24/2017 (340,474 shares). The notice also discloses multiple recent sales by Third Rock Ventures IV, L.P., totaling 2,131,559 shares across August and September 2025 with gross proceeds reported for each trade. The filer attests there is no undisclosed material adverse information and certifies compliance with the notice requirements.
Third Rock Ventures affiliates reported sales of Tango Therapeutics (TNGX) common stock. On 09/05/2025 TRV IV sold 642,906 shares at $7.00 per share and on 09/08/2025 it sold 86,459 shares at a weighted-average price of $7.0395. Following the 09/05 transaction the reporting person disclosed beneficial ownership of 14,813,975 shares and following the 09/08 sale beneficial ownership was reported as 14,727,516 shares. The filing identifies Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., and TRV GP IV, LLC and includes the standard disclaimer that the general partners disclaim beneficial ownership except to the extent of any pecuniary interest.
Tango Therapeutics, Inc. Form 144 notice shows a proposed sale of 86,459 shares of common stock to be executed through BTIG, LLC on 09/08/2025 on the NASDAQ GM, with an aggregate market value listed as $608,628.13. The filing records that these shares were acquired on 03/23/2017 as a pre-IPO investment and that payment was made by wire. The document also discloses sales by Third Rock Ventures IV, L.P. totaling 2,045,100 shares sold on 08/19/2025, 08/22/2025, and 09/05/2025 with combined gross proceeds of $8,718,970.24. The filer attests there is no undisclosed material adverse information.
Tango Therapeutics, Inc. (TNGX) filed a Form 144 reporting a proposed sale of 642,906 common shares through broker BTIG, LLC, with an aggregate market value of $4,461,767 and an indicated approximate sale date of 09/05/2025. The filing shows the shares were originally acquired as a pre-IPO investment on 03/23/2017 and payment for that acquisition was by wire. The filing also discloses sales by Third Rock Ventures IV, L.P. totaling 1,402,194 shares in August 2025 for combined gross proceeds of $9,425,118. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Third Rock Ventures-related entities reported a sale of Tango Therapeutics (TNGX) shares. On 08/22/2025, Third Rock Ventures IV, L.P. sold 302,194 shares of common stock in multiple transactions at a weighted average price of $7.00–$7.05 per share. After the sale, the reporting person holds 15,456,881 shares, held indirectly through the fund and its GP structure. The filing lists Third Rock Ventures IV, L.P., Third Rock Ventures GP IV, L.P., and TRV GP IV, LLC as reporting persons and includes a footnote clarifying the weighted-average price range and the entities' disclaimers of beneficial ownership except to the extent of pecuniary interest.
Tango Therapeutics, Inc. reported that Douglas Barry has resigned from his roles as Chief Legal and Compliance Officer and Corporate Secretary. He notified the board of directors on August 21, 2025, and his resignation will be effective as of September 12, 2025. The company states that he is leaving to pursue another opportunity.